Weekly Semaglutide vs SGLT2 Inhibitors: Direct Comparison in Type 2 Diabetes
Head-to-head comparison of once-weekly semaglutide versus SGLT2 inhibitors in T2D found semaglutide superior for HbA1c and weight loss with different safety profiles.
Quick Facts
What This Study Found
Head-to-head comparison of once-weekly semaglutide versus SGLT2 inhibitors in T2D found semaglutide superior for HbA1c and weight loss with different safety profiles.
Key Numbers
US insurance data from 2018-2022 comparing semaglutide OW versus SGLT2i. Patients had HbA1c ≥ 7.0% at initiation.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide therapeutic knowledge.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to evidence?
- ?Next research?
Trust & Context
- Key Stat:
- Key finding Head-to-head comparison of once-weekly semaglutide versus SGLT2 inhibitors in T2D found semaglutide
- Evidence Grade:
- Based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE).
- Published In:
- Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(5), 1033-1048 (2025)
- Authors:
- Amamoo, James(2), Doshi, Riddhi, Noone, Joshua, Xie, Lin, Gamble, Cory, Guevarra, Mico, Divino, Victoria, Chen, Justin, King, Aaron
- Database ID:
- RPEP-09919
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Head-to-head comparison of once-weekly semaglutide versus SGLT2 inhibitors in T2D found semaglutide superior for HbA1c and weight loss with different safety profiles.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09919APA
Amamoo, James; Doshi, Riddhi; Noone, Joshua; Xie, Lin; Gamble, Cory; Guevarra, Mico; Divino, Victoria; Chen, Justin; King, Aaron. (2025). Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE).. Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(5), 1033-1048. https://doi.org/10.1007/s13300-025-01721-y
MLA
Amamoo, James, et al. "Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE).." Diabetes therapy : research, 2025. https://doi.org/10.1007/s13300-025-01721-y
RethinkPeptides
RethinkPeptides Research Database. "Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter..." RPEP-09919. Retrieved from https://rethinkpeptides.com/research/amamoo-2025-onceweekly-semaglutide-versus-sodiumglucose
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.